The dawn of a new era in treating T-PLL

Oncotarget. 2019 Jan 18;10(6):626-628. doi: 10.18632/oncotarget.26595.

Authors

Alexandra Schrader¹, Till Braun¹, Marco Herling¹

Affiliation

¹ Laboratory of Lymphocyte Signaling and Oncoproteome, Department of Internal Medicine I, Center for Integrated Oncology Köln-Bonn, University of Cologne, Cologne, Germany; Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases and Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.

No abstract available

Keywords: ATM; BCL2 antagonists; HDAC inhibition; T-PLL; p53 reactivation.

Publication types

Editorial